▲ +0.58% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Quest Diagnostics in the last 3 months. The average price target is $139.75, with a high forecast of $158.00 and a low forecast of $120.00. The average price target represents a 0.58% upside from the last price of $138.95.
The current consensus among 12 polled investment analysts is to buy stock in Quest Diagnostics. This rating changed within the last month from a Hold consensus rating.
Quest Diagnostics Incorporated provides diagnostic testing, information, and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine testing, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It offers diagnostic information services primarily under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to patients, clinicians, hospitals, independent delivery networks, health plans, employers, direct contract entities, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile paramedics, nurses, and other health and wellness professionals. The company also provides risk assessment services for the life insurance industry; and healthcare organizations and clinicians robust information technology solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.